iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Marksans Pharma gains on US FDA nod for Cetirizine Hydrochloride tablets

11 Jan 2022 , 03:32 PM

The drug is indicated for the treatment of the perennial allergic rhinitis including sneezing, rhinorrhea, postnasal discharge, watery eyes, running nose.

The product will be marketed under store brand labels and is comparable to the brand Zyrtec.

Marksans Pharma is an Indian pharmaceutical company having a global footprint. The companys strengths lie in research, manufacturing and marketing of finished dosage pharmaceutical formulations.

On a consolidated basis, the company reported an 8.8% fall in net profit to Rs 46.29 crore on a 1.3% rise in net sales to Rs 361 crore in Q2 FY22 over Q2 FY21.

Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.